These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16980907

  • 21. Safety of carrageenan-based gels as preventive microbicides: a narrative review.
    Laurie C, El-Zein M, Franco EL.
    Sex Transm Infect; 2024 Aug 19; 100(6):388-394. PubMed ID: 38849206
    [Abstract] [Full Text] [Related]

  • 22. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa.
    Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z.
    AIDS; 1999 Aug 20; 13(12):1511-5. PubMed ID: 10465075
    [Abstract] [Full Text] [Related]

  • 23. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET, Noguchi LM, Dai JY, Pan J, Biggio J, Hendrix C, Isaacs K, Watts DH, Schwartz JL, Piper J, Beigi R.
    AIDS Behav; 2018 Feb 20; 22(2):402-411. PubMed ID: 28550377
    [Abstract] [Full Text] [Related]

  • 24. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
    Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L.
    AIDS; 2005 Dec 02; 19(18):2157-63. PubMed ID: 16284466
    [Abstract] [Full Text] [Related]

  • 25. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
    Joanis CL, Hart CW.
    AIDS Behav; 2010 Jun 02; 14(3):600-6. PubMed ID: 20049522
    [Abstract] [Full Text] [Related]

  • 26. Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptability.
    Verguet S, Young Holt B, Szeri AJ.
    PLoS One; 2010 Nov 22; 5(11):e15501. PubMed ID: 21124931
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
    Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr 01; 17(4):327-31. PubMed ID: 9525433
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.
    Miller L, Prieto Merino D, Baisley K, Hayes R.
    PLoS One; 2022 Apr 01; 17(5):e0267011. PubMed ID: 35551324
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ, Uckun FM.
    Curr Pharm Des; 2004 Apr 01; 10(3):315-36. PubMed ID: 14754390
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group.
    Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, Perriëns J.
    AIDS; 2000 Jan 07; 14(1):85-8. PubMed ID: 10714571
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.
    Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL.
    N Engl J Med; 1998 Aug 20; 339(8):504-10. PubMed ID: 9709043
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.
    Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu CS, McGowan I.
    AIDS Behav; 2012 Oct 20; 16(7):1761-74. PubMed ID: 21863338
    [Abstract] [Full Text] [Related]

  • 39. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
    Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V.
    Sex Transm Infect; 2000 Apr 20; 76(2):126-30. PubMed ID: 10858715
    [Abstract] [Full Text] [Related]

  • 40. Fourteen-day safety and acceptability study of the universal placebo gel.
    Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, Callahan MM.
    Contraception; 2007 Feb 20; 75(2):136-41. PubMed ID: 17241844
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.